These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
598 related items for PubMed ID: 25400771
1. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Li C, Chen X, Yu X, Zhu Y, Ma C, Xia R, Ma J, Gu C, Ye L, Wu D. Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771 [Abstract] [Full Text] [Related]
2. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Zahran AM, Mohammed Saleh MF, Sayed MM, Rayan A, Ali AM, Hetta HF. Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224 [Abstract] [Full Text] [Related]
3. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients]. Ge MJ, Xu KL, Xu T, Tang YN, Li ZY, Yan ZL, Sun HY, Cheng H, Zhu F, Sang W, Huang YH, Qiu TT, Li DP. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931 [Abstract] [Full Text] [Related]
5. [Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance]. Ma JF, Li CX, Wu DP, Sun ZL, Yan CL. Zhonghua Xue Ye Xue Za Zhi; 2019 Sep 14; 40(9):755-758. PubMed ID: 31648478 [Abstract] [Full Text] [Related]
7. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia. Huang S, Liang C, Zhao Y, Deng T, Tan J, Zha X, Li Y, Chen S. Cytometry B Clin Cytom; 2022 Mar 14; 102(2):143-152. PubMed ID: 34913594 [Abstract] [Full Text] [Related]
11. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia. Tan J, Huang S, Huang J, Yu Z, Chen Y, Lu Y, Li Y, Chen S. Asia Pac J Clin Oncol; 2020 Jun 14; 16(3):137-141. PubMed ID: 32030888 [Abstract] [Full Text] [Related]
14. Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. Cheng G, Li M, Wu J, Ji M, Fang C, Shi H, Zhu D, Chen L, Zhao J, Shi L, Xu B, Zheng X, Wu C, Jiang J. Int J Clin Exp Pathol; 2015 Jun 14; 8(8):9452-7. PubMed ID: 26464703 [Abstract] [Full Text] [Related]
16. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. J Clin Oncol; 2010 Jun 01; 28(16):2739-47. PubMed ID: 20439648 [Abstract] [Full Text] [Related]
17. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Gonçalves Silva I, Gibbs BF, Bardelli M, Varani L, Sumbayev VV. Oncotarget; 2015 Oct 20; 6(32):33823-33. PubMed ID: 26413815 [Abstract] [Full Text] [Related]
18. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia. Zhong L, Jia YQ, Meng WT, Ni X. Arch Pathol Lab Med; 2012 Jan 20; 136(1):84-9. PubMed ID: 22208491 [Abstract] [Full Text] [Related]